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With great interest we read the letter by Cetta et al.
reporting on extensive personal experience in familial
adenomatous polyposis (FAP) patients with thyroid carci-
nomas, liver tumors, and brain tumors.
Cetta and coworkers suggest, based on their own data,
the restriction of thyroid surveillance to patients with
CHRPE or APC mutations before codon 1220. We would
like to emphasize that the population at risk is described
in our manuscript by genotype-phenotype relationship as
depicted in Fig. 1.1 When the mutation is not known, the
demographic characteristics of the population that should
undergo surveillance are described in Table 1. Palpation
of the neck is easy to perform and not time consuming. If
applied in all FAP patients, it has the advantage that this
simple and noninvasive procedure will be surely applied
in those who really are at risk. Indeed, the optional
ultrasound can be used in the subgroups as suggested by
Cetta.
Regarding the comments given by Cetta et al. on
genotype-phenotype correlations in hepatoblastoma, we
would like to draw attention to the legend in our Fig. 1.
The margins of codon regions associated with extraintes-
tinal manifestations are not absolute. Nevertheless, we are
aware that Hirschman et al. have found mutations between
codons 141 and 1750, as we have pointed out in the
written text.2 We would like to underline that excessively
relying on exact boundaries of genotype-phenotype rela-
tionships is not advisable. They merely provide a
guideline.
Further, Cetta et al. suggest other types of liver
tumors in FAP besides hepatoblastoma. Indeed, hepato-
cellular carcinomas (HCC) in FAP patients have been
described in some case reports.3–8 These cases were
assumingly not associated with a history of hepatitis or
alcoholism. Although in some of them a confirmed
germline mutation of the APC gene was noted, no fur-
ther information on tumor characteristics (e.g., loss of
heterozygosity) was given. The association of hepato-
cellular carcinoma and FAP may not be coincidental as
hepatocellular carcinoma is also a tumor with frequent
aberrant activation of b-catenin signaling.9–11 Nuclear or
cytoplasmic accumulation of b-catenin has been observed
in 33%–67%, although mutations of APC and/or b-
catenin genes were only found in about 20%–30% of
HCCs, suggesting that the predominant mechanism(s)
and signaling pathways may be different from that found
in colorectal cancers.11 We agree with the recommen-
dations made by Gruner et al. that APC gene mutation
testing is warranted in the absence of a clear etiology for
HCC in children and adolescents (e.g., hepatitis B), if
there is a strong family history of colon cancer or if the
patient develops known extraintestinal manifestations of
FAP.3 However, the number of case reports is not that
impressive and the relationship may be due to chance. A
similar situation is seen in adrenocortical carcinomas
associated with FAP. These are very rare and to our
knowledge only six cases have been described.12 There-
fore, HCC is not generally considered to be a
manifestation of FAP syndrome.
With regard to brain tumors, we appreciate the efforts of
Cetta to gain more insight into patients at risk. In fact,
national polyposis registries may have an additional
important role to extend this work and collect data on gene
mutations and histology of brain tumors. For now, data on
brain tumors other than medulloblastomas are scarce. It is
interesting to suggest intensive screening for brain tumors
in patients with mutations between codon 140 and 1220
from age 2.13 What kind of surveillance protocol would
suffice in FAP patients, not only from the perspective of
early detection of brain tumors, but also from feasibility
especially at a very young age? As far as we know, no
detailed protocol suggestions have been published. With
great interest we await the results of such a surveillance
study (or the description of personal experience) on the
feasibility, effectiveness, and clinical benefit. Meanwhile,
we would emphasize FAP families and their doctors to be
aware of clinical signs and symptoms of brain tumors.
Heightened suspicion may be warranted for mutations
between codons 140 and 1220, but this remains to be
established.
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